Arvinas Sees Unusually High Options Volume (NASDAQ:ARVN)

Arvinas, Inc. (NASDAQ:ARVN) saw unusually large options trading activity on Friday. Investors purchased 30,996 call options on the stock. This represents an increase of 617% compared to the typical volume of 4,324 call options.

Analyst Upgrades and Downgrades

ARVN has been the subject of several research analyst reports. Guggenheim lowered their price target on shares of Arvinas from $32.00 to $16.00 and set a “buy” rating for the company in a report on Friday, May 2nd. Bank of America decreased their price objective on Arvinas from $54.00 to $28.00 and set a “buy” rating for the company in a report on Wednesday, March 12th. UBS Group decreased their price objective on Arvinas from $74.00 to $21.00 and set a “buy” rating for the company in a report on Thursday, May 15th. Leerink Partners reaffirmed a “market perform” rating and set a $9.00 price target (down previously from $10.00) on shares of Arvinas in a research report on Monday, June 2nd. Finally, Barclays cut their price target on shares of Arvinas from $32.00 to $16.00 and set an “overweight” rating on the stock in a research report on Friday, May 2nd. Ten equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, Arvinas has an average rating of “Moderate Buy” and a consensus target price of $20.29.

Arvinas Stock Down 0.4%

Shares of Arvinas stock opened at $7.44 on Friday. Arvinas has a twelve month low of $5.90 and a twelve month high of $34.11. The company has a market cap of $543.05 million, a price-to-earnings ratio of -11.27 and a beta of 2.19. The company’s 50 day moving average is $7.46 and its 200 day moving average is $12.93.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings data on Thursday, May 1st. The company reported $1.14 EPS for the quarter, beating the consensus estimate of ($0.93) by $2.07. Arvinas had a negative net margin of 10.92% and a negative return on equity of 7.74%. The firm’s revenue was up 646.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.97) EPS. Sell-side analysts expect that Arvinas will post -3.81 EPS for the current fiscal year.

Hedge Funds Weigh In On Arvinas

A number of institutional investors and hedge funds have recently made changes to their positions in the business. GF Fund Management CO. LTD. bought a new stake in Arvinas during the 4th quarter valued at about $28,000. GAMMA Investing LLC lifted its holdings in Arvinas by 11,283.8% during the 1st quarter. GAMMA Investing LLC now owns 4,212 shares of the company’s stock valued at $300,000 after buying an additional 4,175 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in Arvinas by 965.4% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 4,656 shares of the company’s stock valued at $33,000 after buying an additional 4,219 shares in the last quarter. CWM LLC raised its holdings in shares of Arvinas by 2,317.5% in the 1st quarter. CWM LLC now owns 7,615 shares of the company’s stock valued at $53,000 after purchasing an additional 7,300 shares in the last quarter. Finally, KLP Kapitalforvaltning AS bought a new stake in shares of Arvinas in the 4th quarter valued at about $171,000. 95.19% of the stock is owned by hedge funds and other institutional investors.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.